Eaton Vance Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$26.6M Buy
121,700
+10,625
+10% +$2.42M 0.04% 385
2022
Q2
$23.3M Buy
111,075
+30,610
+38% +$6.52M 0.03% 425
2022
Q1
$19.5M Buy
80,465
+34,199
+74% +$8.27M 0.02% 506
2021
Q4
$12.1M Buy
46,266
+1,834
+4% +$476K 0.01% 587
2021
Q3
$11.1M Sell
44,432
-365
-0.8% -$99.8K 0.02% 548
2021
Q2
$11M Buy
44,797
+1,685
+4% +$354K 0.01% 586
2021
Q1
$8.37M Sell
43,112
-1,022
-2% -$205K 0.01% 601
2020
Q4
$9.38M Buy
44,134
+163
+0.4% +$32.5K 0.01% 547
2020
Q3
$7.54M Sell
43,971
-65
-0.1% -$12K 0.01% 539
2020
Q2
$8.46M Sell
44,036
-887
-2% -$145K 0.02% 484
2020
Q1
$6.62M Sell
44,923
-691
-2% -$110K 0.02% 484
2019
Q4
$7.07M Buy
45,614
+21,553
+90% +$3.11M 0.01% 532
2019
Q3
$3.25M Sell
24,061
-297
-1% -$38.9K 0.01% 690
2019
Q2
$2.97M Sell
24,358
-555
-2% -$61.5K 0.01% 711
2019
Q1
$2.59M Sell
24,913
-45,087
-64% -$4.65M 0.01% 708
2018
Q4
$7.97M Buy
70,000
+130
+0.2% +$13.9K 0.02% 418
2018
Q3
$8.06M Buy
69,870
+4,677
+7% +$512K 0.02% 456
2018
Q2
$6.75M Sell
65,193
-51,059
-44% -$5.17M 0.02% 473
2018
Q1
$11.4M Buy
116,252
+100,252
+627% +$9.47M 0.01% 490
2017
Q4
$1.35M Hold
16,000
﹤0.01% 778
2017
Q3
$1.23M Hold
16,000
﹤0.01% 780
2017
Q2
$1.25M Buy
+16,000
New +$1.14M ﹤0.01% 770

Other funds holding RMD

Eaton Vance Management's RMD Position: Q3 2022 in Review

Eaton Vance Management increased its ResMed (RMD) stake by 9.6% in Q3 2022, buying an estimated $2.42M and bringing the position to 121,700 shares worth $26.6M. The position accounts for 0.04% of the portfolio, ranked #385.

Eaton Vance Management first reported a position in RMD in Q2 2017 and has held it in 22 quarters since. 667 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

  • Eaton Vance Management held 121,700 shares of ResMed worth $26.6M as of Q3 2022.
  • Eaton Vance Management bought 10,625 ResMed shares in Q3 2022, an estimated $2.42M.
  • ResMed made up 0.04% of Eaton Vance Management's portfolio in Q3 2022, its #385 holding.
  • Eaton Vance Management first reported a position in ResMed in Q2 2017 and has held it in 22 quarters since.
  • 667 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.